Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MVP
REST API REST API
Homo sapiens
MVP is differentially expressed in 285 experiments: 141 organism parts: lung, brain, ... (139 more);, 195 disease states: normal, control, ... (193 more);, 102 cell types 427 cell lines 34 compound treatments and 75 other conditions.
Synonyms LRP, VAULT1
Orthologs Mvp (Mus musculus)   ENSCING00000009297 (Ciona intestinalis)   mvp (Danio rerio)   MVP (Bos taurus)   MVP (Gallus gallus)   ENSCING00000012199 (Ciona intestinalis)   ENSCING00000012198 (Ciona intestinalis)   Mvp (Rattus norvegicus)   mvp (Xenopus laevis)   MVP (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, cytoplasm, mRNA transport, ribonucleoprotein complex, intracellular membrane-bounded organelle, nucleus, response to drug, nuclear pore, protein transport
InterPro Term Vault_N, MVP_shoulder
UniProt Accession B4DVL1, Q14764
Search EB-eye ENSG00000013364
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (43 experiments)

Factor Value U/D Experiments
SW480
1
3
E-MTAB-37, E-MEXP-1014, E-GEOD-18005, E-GEOD-2509
A549
2
E-GEOD-3202, E-GEOD-6013
BT-474
2
E-GEOD-3529, E-GEOD-5823
HCC2157
2
E-MTAB-37, E-MTAB-62
K562
2
E-MTAB-37, E-GEOD-24147
MCF-10A
2
E-TABM-420, E-GEOD-14990
421 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-19397, E-MEXP-66, E-GEOD-4219, E-GEOD-13909, ... (48 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
endothelial cell
2
E-GEOD-19240, E-GEOD-3998
monocyte
1
2
E-MEXP-583, E-GEOD-11755, E-GEOD-8286
fibroblast
1
E-GEOD-3204
unstimulated polymorphonuclear leukocyte
1
E-GEOD-935
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-16363, E-GEOD-3678, ... (63 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-995, E-MTAB-62, E-GEOD-1729
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-GEOD-4412
prostate carcinoma
1
3
E-MEXP-2034, E-MTAB-62, E-GEOD-3868, E-MEXP-1327
Duchenne muscular dystrophy
2
E-GEOD-1004, E-GEOD-3307
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
neuroblastoma
2
E-MTAB-37, E-MTAB-62
189 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-GEOD-3720, ... (21 experiments)

Factor Value U/D Experiments
none
4
5
E-GEOD-5741, E-MEXP-1230, E-GEOD-412, E-MEXP-1958, E-GEOD-995, ... (9 experiments)
tBHP
1
E-MEXP-2345
BCR/FGFR1
1
E-GEOD-15811
phoshate buffered saline
1
E-GEOD-3720
TTA
1
E-MEXP-2590
doxycycline
1
E-GEOD-2624
28 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-1849, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22541, E-GEOD-2509, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-6919, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-17476, E-GEOD-22593, E-TABM-321, E-GEOD-20115, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-GEOD-12773, E-MEXP-1446, E-GEOD-9764, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-26, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, ... (6 experiments)

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922

Processing time: 0.378 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM